跳至主要内容
临床试验/NCT00877955
NCT00877955撤回1 期

Open-label, Randomized, Single-dose, 2-way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To A Reference Alprazolam Sublingual Tablet

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.0 个研究点开始时间: 2012年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
撤回
发起方
主要终点
Alprazolam bioavailability assessed as area under the concentration-time curve (AUC) and maximum concentration (Cmax)

研究概览

简要总结

This study tests the assumption that the bioavailability of alprazolam from a new sublingual formulation is the same as that from sublingual formulation expected to be used commercially in Brazil.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy male or female subjects
  • BMI 17.5 - 30.5
  • Must provide informed consent

排除标准

  • Clinically significant disease
  • Narrow angle glaucoma
  • Positive drug screen

研究组 & 干预措施

alprazolam sublingual tablet reference

Active Comparator

干预措施: alprazolam sublingual tablet commercial (Drug)

alprazolam sublingual tablet test

Experimental

干预措施: alprazolam sublingual tablet test (Drug)

结局指标

主要结局

Alprazolam bioavailability assessed as area under the concentration-time curve (AUC) and maximum concentration (Cmax)

时间窗: 11 days

次要结局

  • Adverse events, clinical laboratory tests, vital signs(11 days)
  • Alprazolam time of maximum concentration (Tmax) and half life(11 days)

研究者

发起方
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
申办方类型
Industry
责任方
Sponsor

相似试验